1
|
Mohammadinejad A, Aleyaghoob G, Nooranian S, Dima L, Moga MA, Badea M. Development of biosensors for detection of fibrinogen: a review. Anal Bioanal Chem 2024; 416:21-36. [PMID: 37837539 DOI: 10.1007/s00216-023-04976-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2023] [Accepted: 09/20/2023] [Indexed: 10/16/2023]
Abstract
Fibrinogen as a major inflammation marker and blood coagulation factor has a direct impact on the health of humanity. The variations in fibrinogen content lead to risky conditions such as bleeding and cardiovascular diseases. So, accurate methods for monitoring of this glycoprotein are of high importance. The conventional methods, such as the Clauss method, are time consuming and require highly specialized expert analysts. The development of fast, simple, easy to use, and inexpensive methods is highly desired. In this way, biosensors have gained outstanding attention since they offer means for performing analyses at the points-of-care using self-testing devices, which can be applied outside of clinical laboratories or hospital. This review indicates that different electrochemical and optical sensors have been successfully implemented for the detection of fibrinogen under normal levels of fibrinogen in plasma. The biosensors for the detection of fibrinogen have been designed based on the quartz crystal microbalance, field-effect transistor, electrochemical impedance spectroscopy, amperometry, surface plasmon resonance, localized surface plasmon resonance, and colorimetric techniques. Also, this review demonstrates the utility of the application of nanoparticles in different detection techniques.
Collapse
Affiliation(s)
- Arash Mohammadinejad
- Department of Fundamental, Prophylactic and Clinical Disciplines, Faculty of Medicine, Transilvania University of Brasov, Brașov, Romania
- Research Center for Fundamental Research and Prevention Strategies in Medicine, Research and Development Institute of Transilvania University of Brasov, Brașov, Romania
| | - Ghazaleh Aleyaghoob
- Department of Medical Biotechnology and Nanotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
- Department of Chemistry, Payame Noor University, Tehran, 19395-4697, Iran
| | - Samin Nooranian
- Department of Medical Biotechnology and Nanotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Lorena Dima
- Department of Fundamental, Prophylactic and Clinical Disciplines, Faculty of Medicine, Transilvania University of Brasov, Brașov, Romania
- Research Center for Fundamental Research and Prevention Strategies in Medicine, Research and Development Institute of Transilvania University of Brasov, Brașov, Romania
| | - Marius Alexandru Moga
- Department of Medical and Surgical Specialties, Faculty of Medicine, Transilvania University of Brasov, Brașov, Romania
- Centre for Applied Medicine and Intervention Strategies in Medical Practice, Research and Development Institute of Transilvania University of Brasov, Brașov, Romania
| | - Mihaela Badea
- Department of Fundamental, Prophylactic and Clinical Disciplines, Faculty of Medicine, Transilvania University of Brasov, Brașov, Romania.
- Research Center for Fundamental Research and Prevention Strategies in Medicine, Research and Development Institute of Transilvania University of Brasov, Brașov, Romania.
| |
Collapse
|
2
|
Iqbal R, Khan S, Ali HM, Khan M, Wahab S, Khan T. Application of nanomaterials against SARS-CoV-2: An emphasis on their usefulness against emerging variants of concern. FRONTIERS IN NANOTECHNOLOGY 2022. [DOI: 10.3389/fnano.2022.1060756] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Researchers are now looking to nanomaterials to fight serious infectious diseases that cause outbreaks and even pandemics. SARS-CoV-2 brought chaos to almost every walk of life in the past 2 years and has challenged every available treatment method. Although vaccines were developed in no time against it, the most pressing issue was the emergence of variants of concern arising because of the rapidly evolving viral strains. The higher pathogenicity and, in turn, the higher mortality rate of infections caused by these variants renders the existing vaccines less effective and the effort to produce further vaccines a costly endeavor. While several techniques, such as immunotherapy and repurposed pharmaceutical research, are being studied to minimize viral infection, the fundamentals of nanotechnology must also be considered to enhance the anti-SARS-CoV-2 efforts. For instance, silver nanoparticles (AgNPs) have been applied against SARS-CoV-2 effectively. Similarly, nanomaterials have been tested in masks, gloves, and disinfectants to aid in controlling SARS-CoV-2. Nanotechnology has also contributed to diagnoses such as rapid and accurate detection and treatment such as the delivery of mRNA vaccines and other antiviral agents into the body. The development of polymeric nanoparticles has been dubbed a strategy of choice over traditional drugs because of their tunable release kinetics, specificity, and multimodal drug composition. Our article explores the potential of nanomaterials in managing the variants of concern. This will be achieved by highlighting the inherent ability of nanomaterials to act against the virus on fronts such as inhibition of SARS-CoV-2 entry, inhibition of RNA replication in SARS-CoV-2, and finally, inhibition of their release. In this review, a detailed discussion on the potential of nanomaterials in these areas will be tallied with their potential against the current and emerging future variants of concern.
Collapse
|
3
|
Essa RZ, Wu YS, Batumalaie K, Sekar M, Poh CL. Antiviral peptides against SARS-CoV-2: therapeutic targets, mechanistic antiviral activity, and efficient delivery. Pharmacol Rep 2022; 74:1166-1181. [PMID: 36401119 PMCID: PMC9676828 DOI: 10.1007/s43440-022-00432-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2022] [Revised: 10/28/2022] [Accepted: 10/31/2022] [Indexed: 11/19/2022]
Abstract
The global pandemic of COVID-19 is a serious public health concern. Over 625 million confirmed cases and more than 6 million deaths have been recorded worldwide. Although several vaccines and antiviral medications have been developed, their efficacy is limited by the emerging new SARS-CoV-2 strains. Peptide-based therapeutics is a fast-growing class of new drugs and have unique advantages over large proteins and small molecules. Antiviral peptides (AVPs) are short polycationic antivirals with broad-spectrum effects, which have been shown to exert both prophylactic and therapeutic actions against reported coronaviruses. The potential therapeutic targets of AVPs are located either on the virus (e.g., E-protein and S-protein) to prohibit viral binding or host cells, particularly, those present on the cell surface (e.g., ACE2 and TMPRSS2). Despite AVPs having promising antiviral effects, their efficacy is limited by low bioavailability. Thus, nanoformulation is a prerequisite for prolonged bioavailability and efficient delivery. This review aimed to present an insight into the therapeutic AVP targets on both virus and host cells by discussing their antiviral activities and associated molecular mechanisms. Besides, it described the technique for discovering and developing possible AVPs based on their targets, as well as the significance of using nanotechnology for their efficient delivery against SARS-CoV-2.
Collapse
Affiliation(s)
- Raahilah Zahir Essa
- Department of Medical Sciences, School of Medical and Life Sciences, Sunway University, 47500 Selangor, Malaysia
| | - Yuan-seng Wu
- Centre for Virus and Vaccine Research, School of Medical and Life Sciences, Sunway University, 47500 Selangor, Malaysia
- Department of Biological Sciences, School of Medical and Life Sciences, Sunway University, 47500 Selangor, Malaysia
| | - Kalaivani Batumalaie
- Department of Biomedical Sciences, Faculty of Health Sciences, Asia Metropolitan University, 81750 Johor, Malaysia
| | - Mahendran Sekar
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Health Sciences, Royal College of Medicine Perak, Universiti Kuala Lumpur, 30450 Ipoh, Perak Malaysia
| | - Chit-laa Poh
- Centre for Virus and Vaccine Research, School of Medical and Life Sciences, Sunway University, 47500 Selangor, Malaysia
| |
Collapse
|
4
|
Zhang W, Liu N, Zhang J. Functional nucleic acids as modular components against SARS-CoV-2: From diagnosis to therapeutics. Biosens Bioelectron 2022; 201:113944. [PMID: 35026546 PMCID: PMC8718887 DOI: 10.1016/j.bios.2021.113944] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2021] [Revised: 11/28/2021] [Accepted: 12/28/2021] [Indexed: 01/05/2023]
Abstract
Coronavirus Disease 2019 (COVID-19), which poses an extremely serious global impact on human public healthcare, represents a high transmission and disease-causing viral infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that is expanding at a rapid pace. Therefore, it is urgent for researchers to establish effective platforms for the assay and treatment of SARS-CoV-2. Functional nucleic acids (FNAs), comprising aptamers and nucleases, are of primary concern within the biological and medical communities owing of the distinctive properties of their target recognition and catalysis. This review will concentrate on the essential aspects of insights regarding FNAs and their technological expertise for the diagnostic and therapeutic utilization against COVID-19. We first offer a historical perspective of the COVID-19 pandemics, its clinical characteristics and potential biomarkers. Then, we briefly discuss the current diagnostic and therapeutic methodology towards COVID-19, highlighting the superiorities and existing shortcomings. After that, we introduce the key features of FNAs, and summarize recent progress of in vitro selection of FNAs for SARS-CoV-2 specific proteins and RNAs, followed by highlighting the general concept of translating FNAs into functional probes for diagnostic and therapeutic purposes. Then, we critically review the emerging FNAs-based diagnostic and therapeutic strategies that are fast, precise, efficient, and highly specific to fight COVID-19. Finally, we identify remaining challenges and offer future outlook of this emerging field.
Collapse
Affiliation(s)
- Wenxian Zhang
- State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Chemistry and Biomedicine Innovation Center (ChemBIC), Nanjing University, Nanjing, 210023, China
| | - Na Liu
- State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Chemistry and Biomedicine Innovation Center (ChemBIC), Nanjing University, Nanjing, 210023, China
| | - Jingjing Zhang
- State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Chemistry and Biomedicine Innovation Center (ChemBIC), Nanjing University, Nanjing, 210023, China.
| |
Collapse
|
5
|
Halima HB, Errachid A, Jaffrezic‐Renault N. Electrochemical Affinity Sensors Using Field Effect Transducer Devices for Chemical Analysis. ELECTROANAL 2021. [DOI: 10.1002/elan.202100451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Hamdi Ben Halima
- University of Lyon Institute of Analytical Sciences 69100 Villeurbanne France
| | - Abdelhamid Errachid
- University of Lyon Institute of Analytical Sciences 69100 Villeurbanne France
| | | |
Collapse
|
6
|
Martín J, Tena N, Asuero AG. Current state of diagnostic, screening and surveillance testing methods for COVID-19 from an analytical chemistry point of view. Microchem J 2021; 167:106305. [PMID: 33897053 PMCID: PMC8054532 DOI: 10.1016/j.microc.2021.106305] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2021] [Revised: 04/12/2021] [Accepted: 04/14/2021] [Indexed: 12/18/2022]
Abstract
Since December 2019, we have been in the battlefield with a new threat to the humanity known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this review, we describe the four main methods used for diagnosis, screening and/or surveillance of SARS-CoV-2: Real-time reverse transcription polymerase chain reaction (RT-PCR); chest computed tomography (CT); and different complementary alternatives developed in order to obtain rapid results, antigen and antibody detection. All of them compare the highlighting advantages and disadvantages from an analytical point of view. The gold standard method in terms of sensitivity and specificity is the RT-PCR. The different modifications propose to make it more rapid and applicable at point of care (POC) are also presented and discussed. CT images are limited to central hospitals. However, being combined with RT-PCR is the most robust and accurate way to confirm COVID-19 infection. Antibody tests, although unable to provide reliable results on the status of the infection, are suitable for carrying out maximum screening of the population in order to know the immune capacity. More recently, antigen tests, less sensitive than RT-PCR, have been authorized to determine in a quicker way whether the patient is infected at the time of analysis and without the need of specific instruments.
Collapse
Key Words
- 2019-nCoV, 2019 novel coronavirus
- ACE2, Angiotensin-Converting Enzyme 2
- AI, Artificial Intelligence
- ALP, Alkaline Phosphatase
- ASOs, Antisense Oligonucleotides
- Antigen and antibody tests
- AuNIs, Gold Nanoislands
- AuNPs, Gold Nanoparticles
- BSL, Biosecurity Level
- CAP, College of American Pathologists
- CCD, Charge-Coupled Device
- CG, Colloidal Gold
- CGIA, Colloidal Gold Immunochromatographic Assay
- CLIA, Chemiluminescence Enzyme Immunoassay
- CLIA, Clinical Laboratory Improvement Amendments
- COVID-19
- COVID-19, Coronavirus disease-19
- CRISPR, Clustered Regularly Interspaced Short Palindromic Repeats
- CT, Chest Computed Tomography
- Cas, CRISPR Associate Protein
- China CDC, Chinese Center for Disease Control and Prevention
- Ct, Cycle Threshold
- DETECTR, SARS-CoV-2 DNA Endonuclease-Targeted CRISPR Trans Reporter
- DNA, Dexosyrosyribonucleic Acid
- E, Envelope protein
- ELISA, Enzyme Linked Immunosorbent Assay
- EMA, European Medicines Agency
- EUA, Emergence Use Authorization
- FDA, Food and Drug Administration
- FET, Field-Effect Transistor
- GISAID, Global Initiative on Sharing All Influenza Data
- GeneBank, Genetic sequence data base of the National Institute of Health
- ICTV, International Committee on Taxonomy of Viruses
- IgA, Immunoglobulins A
- IgG, Immunoglobulins G
- IgM, Immunoglobulins M
- IoMT, Internet of Medical Things
- IoT, Internet of Things
- LFIA, Lateral Flow Immunochromatographic Assays
- LOC, Lab-on-a-Chip
- LOD, Limit of detection
- LSPR, Localized Surface Plasmon Resonance
- M, Membrane protein
- MERS-CoV, Middle East Respiratory Syndrome Coronavirus
- MNP, Magnetic Nanoparticle
- MS, Mass spectrometry
- N, Nucleocapsid protein
- NER, Naked Eye Readout
- NGM, Next Generation Molecular
- NGS, Next Generation Sequencing
- NIH, National Institute of Health
- NSPs, Nonstructural Proteins
- Net, Neural Network
- ORF, Open Reading Frame
- OSN, One Step Single-tube Nested
- PDMS, Polydimethylsiloxane
- POC, Point of Care
- PPT, Plasmonic Photothermal
- QD, Quantum Dot
- R0, Basic reproductive number
- RBD, Receptor-binding domain
- RNA, Ribonucleic Acid
- RNaseH, Ribonuclease H
- RT, Reverse Transcriptase
- RT-LAMP, Reverse Transcription Loop-Mediated Isothermal Amplification
- RT-PCR, Real-Time Reverse Transcription Polymerase Chain Reaction
- RT-PCR, chest computerized tomography
- RdRp, RNA-Dependent RNA Polymerase
- S, Spike protein
- SARS-CoV-2
- SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2
- SERS, Surface Enhanced Raman Spectroscopy
- SHERLOCK, Specific High Sensitivity Enzymatic Reporter UnLOCKing
- STOPCovid, SHERLOCK Testing on One Pot
- SVM, Support Vector Machine
- SiO2@Ag, Complete silver nanoparticle shell coated on silica core
- US CDC, US Centers for Disease Control and Prevention
- VOC, Variant of Concern
- VTM, Viral Transport Medium
- WGS, Whole Genome Sequencing
- WHO, World Health Organization
- aM, Attomolar
- dNTPs, Nucleotides
- dPCR, Digital PCR
- ddPCR, Droplet digital PCR
- fM, Femtomolar
- m-RNA, Messenger Ribonucleic Acid
- nM, Nanomolar
- pM, Picomolar
- pfu, Plaque-forming unit
- rN, Recombinant nucleocapsid protein antigen
- rS, Recombinant Spike protein antigen
- ssRNA, Single-Stranded Positive-Sense RNA
Collapse
Affiliation(s)
- Julia Martín
- Departamento de Química Analítica, Escuela Politécnica Superior, Universidad de Sevilla, C/ Virgen de África 7, Sevilla E-41011, Spain
| | - Noelia Tena
- Departamento de Química Analítica, Facultad de Farmacia, Universidad de Sevilla, Prof. García González, 2, Sevilla 41012, Spain
| | - Agustin G Asuero
- Departamento de Química Analítica, Facultad de Farmacia, Universidad de Sevilla, Prof. García González, 2, Sevilla 41012, Spain
| |
Collapse
|